BRAF and neoplasm: Apart from its role in tumor initiation and progression, recent results from our group demonstrated that IKKα, and, in particular, IKKα(p45), is activated not only in cancer cells carrying mutant BRAF, but also in cells possessing wild-type KRAS and BRAF in response to stimuli that induce DNA damage, such as chemotherapy or irradiation[4].